# Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)

> **NCT05640778** · PHASE2 · UNKNOWN · sponsor: **Second Affiliated Hospital, School of Medicine, Zhejiang University** · enrollment: 30 (estimated)

## Conditions studied

- Luminal B/HER2-negative Breast Cancer

## Interventions

- **DRUG:** Dalpiciclib combined with aromatase inhibitors

## Key facts

- **NCT ID:** NCT05640778
- **Lead sponsor:** Second Affiliated Hospital, School of Medicine, Zhejiang University
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2022-10-01
- **Primary completion:** 2024-10-31
- **Final completion:** 2025-10-31
- **Target enrollment:** 30 (ESTIMATED)
- **Last updated:** 2024-01-31

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05640778

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05640778, "Neoadjuvant Dalpiciclib Plus Aromatase Inhibitors in Luminal B/HER2-negative Breast Cancer (DANCER)". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT05640778. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*